ProfileGDS5678 / 1425978_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 36% 37% 37% 35% 36% 40% 37% 36% 36% 37% 37% 36% 37% 37% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8568136
GSM967853U87-EV human glioblastoma xenograft - Control 22.8436137
GSM967854U87-EV human glioblastoma xenograft - Control 32.8517637
GSM967855U87-EV human glioblastoma xenograft - Control 42.7555435
GSM967856U87-EV human glioblastoma xenograft - Control 52.7645236
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9970340
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9139237
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8160336
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7894836
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.825837
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8317237
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7891336
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8395737
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8378437